KOSPIBiotech & Pharma249420

Il Dong Pharmaceutical

₩11,910▼ 1.24%2026-11-18 close
Market Cap
₩376.8B
Turnover
₩900M
Volume
70K
Shares out.
31.6M
PER
24.1×
PBR
1.6×
EPS
₩521
Dividend Yield
1.59%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩200 per share · Prices as of the 2026-11-18 close

01

Report overview

Profit recovery confirmed; pipeline and Q3 loss are the tests

Operating profit and attributable net income turned positive in 2025, but Q3 2026 swung back to an attributable net loss, leaving earnings durability and pipeline results as the open tests.

  1. 1

    Operating profit rose 48.5% to KRW 19.5 billion in 2025, and attributable net income turned to a profit of KRW 27.7 billion.

  2. 2

    Q3 2026 operating profit was KRW 7.14 billion, up 5.7% year on year, yet an attributable net loss of KRW 4.76 billion marked a swing back into the red.

  3. 3

    Revenue fell from KRW 637.7 billion in 2022 to KRW 566.9 billion in 2025, while operating margin edged up to 3.4% in 2025 from 2.1% in 2024.

  4. 4

    The oral GLP-1 obesity candidate has cleared Phase 1 on efficacy and safety, while the P-CAB reflux candidate ID120040002 is in a domestic Phase 3 trial.

  5. 5

    Near-term earnings rest on in-licensed prescription drugs and consumer healthcare, while new-drug revenue depends on clinical results and approvals.

02

Business structure

IL Dong Pharmaceutical manufactures and sells medicines, raw materials, health supplements and special nutrition foods. Its key medicines include the active vitamin brand Aronamin and the antibiotic Furamarin. The business is organized into prescription drugs (ETC), over-the-counter drugs and healthcare.

In 2026 the company widened its prescription portfolio, signing an exclusive domestic distribution and sales deal for urology drugs with Viatris Korea and taking on domestic distribution and co-promotion of the migraine drug Nurtec ODT from Pfizer Korea.

In-licensed products can generate sales faster than internally developed drugs because they use the existing sales network. On contract manufacturing, the company presented its dedicated antibiotic and anticancer facilities and raw-material supply model to overseas partners at CPhI 2026 in October.

The healthcare line includes probiotics, health functional foods and consumer brands. In June 2026 it absorbed its drug-discovery subsidiary, bringing R&D staff and pipelines in-house. No verifiable segment revenue split is disclosed, so the relative weight of each business is not quantified here.

In the P-CAB reflux market, two products already on the domestic market hold the leading positions, so the follow-on candidate ID120040002 must prove differentiation.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩145.5B₩6.8B4.6%
2025Q4₩147B₩7.9B5.4%
2026Q1₩142B₩9.2B6.5%
2026Q2₩147.9B₩2B1.3%
2026Q3₩151B₩7.1B4.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩637.7B-₩73.5B-₩141.6B−11.5%−74.0%230.8%
2023₩600.8B-₩53.9B-₩78.9B−9.0%−46.6%250.8%
2024₩614.9B₩13.1B-₩4.6B2.1%−2.8%270.3%
2025₩566.9B₩19.5B₩27.7B3.4%11.2%139.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

On an annual basis, revenue shrank while earnings moved from losses into profit. Revenue was highest in 2022 at KRW 637.7 billion and lowest in 2025 at KRW 566.9 billion, with KRW 600.8 billion in 2023 (down 5.8% year on year) and KRW 614.9 billion in 2024 (up 2.4%).

Operating loss narrowed from KRW 73.5 billion in 2022 to KRW 53.9 billion in 2023, then turned into operating profit of KRW 13.1 billion in 2024 and rose 48.5% to KRW 19.5 billion in 2025.

Attributable net loss shrank from KRW 141.6 billion in 2022 and KRW 78.9 billion in 2023 to KRW 4.58 billion in 2024, before turning into attributable net income of KRW 27.7 billion in 2025.

Net income including non-controlling interests was KRW 23.7 billion in 2025, a different figure because of the non-controlling share. Operating margin moved from -11.5% in 2022 to 3.4% in 2025, and the debt-to-equity ratio fell from 270.3% in 2024 to 139.2% in 2025.

At the end of 2025, total liabilities were KRW 333.5 billion and total equity was KRW 239.5 billion. Operating cash flow went from -KRW 53.5 billion in 2022 and -KRW 36.6 billion in 2023 to KRW 28.3 billion in 2024 and KRW 19 billion in 2025.

Quarterly revenue went from KRW 145.5 billion in Q3 2025 to a low of KRW 142 billion in Q1 2026, then rose to KRW 147.9 billion in Q2 and KRW 151 billion in Q3, up 3.8% year on year.

Operating profit rose from KRW 6.76 billion in Q3 2025 to KRW 7.93 billion in Q4 and KRW 9.23 billion in Q1 2026, fell to KRW 1.98 billion in Q2 (down 78.5% quarter on quarter), and recovered to KRW 7.14 billion in Q3.

Attributable net income fell from KRW 22.4 billion in Q3 2025 to KRW 7.24 billion in Q4, KRW 8.27 billion in Q1 2026 and KRW 5.7 billion in Q2, then swung to an attributable net loss of KRW 4.76 billion in Q3.

The company attributed the Q1 2026 improvement to better cost of sales from cost innovation and lower debt and interest expenses, and attributable net income over the last four quarters totaled KRW 16.4 billion.

05

Industry analysis

For the domestic drug market, the key variable in 2026 is the revision of the drug pricing system. At the 2026 New Year ceremony, the group chairman pointed to large changes such as drug price cuts and stressed preparation.

In prescription drugs, in-licensed products fill revenue in a short period, while internally developed drugs have commercialization timing set by clinical and approval outcomes. The obesity drug market is shifting from injectables toward oral products.

A brokerage report from November 2025 noted that several global competing compounds struggled with liver-related problems, which limited dose escalation or weight-loss efficacy. The same report judged that the company's candidate showed liver-related markers improving.

That assessment rests on Phase 1 results, so reproducibility in later trials is the key test. In the P-CAB market, HK inno.N and Daewoong Pharmaceutical already hold leading positions, so the follow-on reflux candidate must demonstrate differentiation.

The company's competitive strength lies in contract manufacturing backed by GMP-certified facilities, while prescription drug distribution and consumer healthcare continue to anchor earnings until new-drug results arrive.

06

Outlook

The company's 2026 management theme is 'ID 4.0, creating competitive advantage through results,' with two headline targets: revenue and profit performance, and securing new growth drivers. Improving profitability through cost innovation and portfolio restructuring is presented as the central task.

In new-drug R&D, the company plans to pursue out-licensing overseas and open innovation actively. The company said the oral GLP-1 obesity candidate ID110521156 showed superior efficacy and safety versus competing compounds in Phase 1.

Related reports mention plans to enter global Phase 2 in 2026 and to pursue technology-transfer talks with a big pharma company. The P-CAB reflux candidate ID120040002 is in a domestic Phase 3 trial, and the company said global commercialization discussions took place at CPhI in October 2026.

The autoimmune and fibrosis candidate IL21120033 was targeted for clinical trial application in Q3 2026, and the cyclin K degrader IL2106 for a rare cancer indication was targeted for Q4 2026. Overseas business is being diversified through contract manufacturing and OEM/ODM models, extending into healthcare and beauty.

On earnings, the next checkpoint is whether the revenue contribution from in-licensed prescription drugs and the cost-ratio gains persist in later quarters. New-drug revenue remains limited in timing and scale by clinical results and approvals.

07

Valuation

PER
24.1×
PBR
1.6×
ROE
6.8%
EPS
₩521
BPS
₩7,935
Dividend per share
₩200

The current multiples sit on a base where annual profit has turned positive but quarterly earnings remain small, so a modest swing in a single quarter can move the multiples sharply. The price-to-book ratio reflects a premium over net asset value, and market capitalization is above total equity at the end of 2025.

Brokerage reports since late 2025 have described a re-rating of the company's value on expectations for an oral obesity drug. In November 2025, the share price rose more than 17% in a single day on oral obesity drug expectations, showing sensitivity to pipeline news.

Attributable net income over the last four quarters totaled KRW 16.4 billion, and the Q3 2026 swing to a net loss means earnings-based multiples are heavily affected by quarterly swings.

Dividend yield should be read alongside the industry average, and dividend policy is an item to check together with the earnings trend.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Improving earnings profile

Operating margin rose from -11.5% in 2022 to 3.4% in 2025, and Q3 2026 operating profit of KRW 7.14 billion was up 5.7% year on year. The company points to cost innovation and a portfolio shift toward higher-margin products as the drivers. Attributable net income was in the black in every quarter from Q3 2025 through Q2 2026.

Pipeline progress

The company said the oral GLP-1 candidate ID110521156 showed superior efficacy and safety versus competing compounds in Phase 1. The P-CAB candidate ID120040002 is in a domestic Phase 3 trial, and global partnering discussions took place in October 2026. A technology transfer deal would bring upfront payments and milestone fees.

Wider prescription drug base

Exclusive domestic distribution for urology drugs with Viatris Korea and the distribution and co-promotion of Nurtec ODT with Pfizer Korea widened the prescription drug base. In-licensed products can build sales in a short period by using the existing sales network. The shift toward a larger prescription drug share is under way from a 2025 revenue base of KRW 566.9 billion.

09

Bear factors

High quarterly earnings volatility

Attributable net loss of KRW 4.76 billion in Q3 2026 marked a swing into the red year on year, and Q2 operating profit of KRW 1.98 billion fell 78.5% quarter on quarter. Quarterly profit has shown sharp swings. Whether operating gains carry through to net income and cash flow remains the open question.

Slow revenue recovery

Revenue fell from KRW 637.7 billion in 2022 to KRW 566.9 billion in 2025. Q3 2026 revenue of KRW 151 billion was up only 3.8% year on year. If top-line recovery trails the margin gains, scale benefits stay limited.

Pipeline commercialization uncertainty

New-drug commercialization timing and revenue depend on clinical results and approvals. For the obesity candidate, the question is whether Phase 1 results can be reproduced in later trials. The P-CAB market is already held by two products, so the follower must prove differentiation.

10

Risk factors

Clinical and approval risk

Key candidates are still in clinical stages, so their value depends on later-stage results and approvals. If Phase 1 efficacy and safety do not replicate in later trials, the terms of technology-transfer talks could weaken. The P-CAB candidate must prove differentiation from existing products.

Drug pricing and policy risk

At the 2026 New Year ceremony, the group chairman pointed to large changes such as drug price cuts. Revisions to the pricing system directly affect the profitability of prescription and over-the-counter drugs. If price cuts are steep, gains from lower cost of sales could be offset.

Balance sheet burden

The debt-to-equity ratio fell from 270.3% in 2024 to 139.2% in 2025, but the debt burden remains. Operating cash flow was KRW 19 billion in 2025, a modest cushion for interest costs and debt repayment.

11

What to watch next

  1. December 2026 (Q4 target)

    Target timing for the clinical trial application for the cyclin K degrader IL2106 in a rare cancer indication. Submission would signal the pipeline moving into clinical stages.

  2. Early 2027 (annual preliminary results)

    Shows how 2026 full-year operating profit and attributable net income moved versus 2025. The key is how much the Q3 net loss weighed on the annual trend.

  3. Late March 2027 (2026 annual report deadline)

    The regular report will show quarterly profit line items, debt and cash flow, and the detailed drivers of the Q2 operating profit drop.

  4. Timing undetermined (after November 2026)

    Whether the oral GLP-1 candidate enters global Phase 2 and whether a technology-transfer deal is signed. A deal could add upfront and milestone payments to the earnings structure.

12

Overall view

IL Dong Pharmaceutical has shifted from an operating loss in 2022 to operating profit of KRW 19.5 billion and attributable net income of KRW 27.7 billion in 2025. Revenue fell from KRW 637.7 billion in 2022 to KRW 566.9 billion in 2025, yet operating margin reached 3.4%.

The debt-to-equity ratio dropped from 270.3% in 2024 to 139.2% in 2025. However, an attributable net loss of KRW 4.76 billion in Q3 2026 means the durability of profit is still being tested.

In-licensed prescription drugs and cost gains are supporting earnings, and whether clinical results translate into commercial value is the central variable for the pipeline.

Bullish factors are the improved earnings profile and the obesity and P-CAB pipeline, while bearish factors are quarterly volatility, the Q3 swing to a loss, the debt burden and drug pricing policy.

The next checkpoints are the 2026 full-year preliminary results and the 2026 annual report, along with the IL2106 trial application and progress on technology transfer for the oral candidate.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. m.news.nate.com
  2. medicaltimes.com
  3. comp.wisereport.co.kr
  4. newsway.co.kr
  5. kpanews.co.kr
  6. digitaltoday.co.kr
  7. meerae.ai
  8. biz.newdaily.co.kr
  9. jasoseol.com
  10. v.daum.net
  11. news.nate.com
  12. markets.hankyung.com
  13. news.nate.com
  14. businesspost.co.kr
  15. hitnews.co.kr
  16. lcnews.co.kr
  17. littlebproject.com
  18. etoday.co.kr

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis